R., Apperley, L., Parkinson, J., Clark, K., Lund, K., Owens, M., & Senniappan, S
[1] Ozempic works by mimicking the action of naturally occurring GLP-1, a hormone released by the intestines in response to food intake
The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear: Average weight loss with tirzepatide: 20.2% Average weight loss with semaglutide: 13.7% Tirzepatide patients were also more likely to hit major milestones 10%, 15%, 20%, and even 25% body weight loss
Notes: Our recommended vendor supplies BPC-157/TB-500 capsules in 60-day containers, which represents a 60-day supply per test subject
This innovative drug is designed to block DHT specifically at the scalp, critically avoiding the systemic hormonal side effects associated with older treatments